idrabiotaparinux: a biotinylated form of idraparinux with anticoagulant properties [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16202213 |
| MeSH ID | M0542155 |
| Synonym |
|---|
| 774531-07-6 |
| idrabiotaparinux |
| h44r6rjt3s , |
| unii-h44r6rjt3s |
| idrabiotaparinux [who-dd] |
| Q27279616 |
Idrabiotaparinux is a biotinylated version of idraparinux.Its activity can be reversed with avidin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Idrabiotaparinux is a biotinylated version of idraparinux; its activity can be reversed with avidin." | ( Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. Boëlle, E; Cortez, P; Destors, JM; Paty, I; Sanderink, G; Trellu, M, 2010) | 1.35 |
Idrabiotaparinux has an attached biotin moiety at the non-reducing end unit. This allows its neutralisation with avidin, an egg-derived protein with low antigenicity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Idrabiotaparinux has an attached biotin moiety at the non-reducing end unit, which allows its neutralisation with avidin, an egg-derived protein with low antigenicity." | ( Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Harenberg, J, 2009) | 1.36 |
| "Idrabiotaparinux has a similar time course of FXa inhibition, efficacy and safety to idraparinux for the treatment of deep venous thrombosis." | ( Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. , 2011) | 2.07 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]." | ( New anticoagulants for atrial fibrillation. Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M, 2009) | 0.35 |
| "Pharmacodynamic parameters reported after single dose in healthy volunteers and after repeated once weekly dosing in patients demonstrated the bioequipotency of idrabiotaparinux and idraparinux based on FXa inhibition." | ( Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. Boëlle, E; Cheng, S; Cortez, P; Donat, F; Fau, JB; Paty, I; Sanderink, GJ; Trellu, M, 2013) | 0.87 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (31.25%) | 5.53% |
| Reviews | 8 (50.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (18.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week [NCT00311090] | Phase 3 | 757 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| An International, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Study of 3-month or 6-month Treatment With SSR126517E (3.0 mg s.c. Once-weekly) Versus Oral INR-adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonar [NCT00345618] | Phase 3 | 3,202 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Th [NCT00580216] | Phase 3 | 3,773 participants (Actual) | Interventional | 2007-12-31 | Terminated(stopped due to early discontinuation based on strategic sponsor decision not driven by any safety concern) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||